Development Path
2023
· HEC, an A-share listed company (600673.SH), Zunyi Municipal Government and GAC Group reached a strategic cooperation to improve the layout of the new energy industry
· HEC Pharm R&D Center was restructured and renamed Sunshine Lake Pharma Co., Ltd. ("HEC Pharma")
2021
·HEC Pharmaceutical Research Institute completed A round of financing of nearly 7 billion yuan
·HEC Pharmaceutical Research Institute completed the equity control of HEC Changjiang Pharmaceutical (01558.HK), realizing the integration of pharmaceutical assets
2020
·Mr. Zhang Yushuai took over as chairman of HEC Group and established a new board of directors of HEC Group. HEC officially entered the 2.0 new era of "co-creation, co-responsibility and sharing"
·HEC's first Class 1.1 original innovative drug "Emitasvir Phosphate" was approved for marketing
2019
2018
·Cordyceps sinensis (breeding product) was included in "Guangdong Province Local Medicinal Materials Standard" (Volume 3)
·"Research on key technologies of Cordyceps sinensis breeding and its industrial application" won the first prize of Guangdong Science and Technology Progress Award
2017
2016
2015
·HEC Changjiang Pharmaceutical was listed on the main board of Hong Kong, stock code: 01558.HK
·HEC Pharmaceutical Research Institute is approved by the Ministry of Science and Technology of the People's Republic of China to establish a "State Key Laboratory of New Anti-infective Drug Research and Development"
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
Zunyi Base in Guizhou started construction
2003
·HEC A-share backdoor listing, stock code: 600673.SH
·Dongguan Songshan Lake Factory started construction
2002
·Guangdong Dongguan Base started construction
·Acquired Hubei Changhe Pharmaceutical Co., Ltd. and officially entered the pharmaceutical industry
2001
2000
1999
1998
1997
WeChat public account
2022 Copyright by HEC Group 粵ICP備19034764號-1